Relationship between the effect of roxadustat and comorbidity of diabetes in non-dialysis patients with chronic kidney disease

Relationship between the effect of roxadustat and comorbidity of diabetes in non-dialysis patients with chronic kidney disease - Relationship between the effect of roxadustat and comorbidity of diabetes in non-dialysis patients with chronic kidney disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050812

Enrollment

Registered

2023-04-11

Start date

2021-08-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal anemia, chronic kidney disease, diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-dialysis patients with chronic kidney disease and renal anemia

Exclusion criteria

Exclusion criteria: Patients who were transferred to another hospital within a month after the initiation of roxadustat Patients whose hemoglobin level of 11 g/dL or higher at the initiation of roxadustat

Design outcomes

Primary

Measure	Time frame
The changes in the dose over 6 months after initiation of roxadustat	—

Secondary

Measure	Time frame
Changes in hemoglobin levels and achievement rates of target hemoglobin levels over 6 months after initiation of roxadustat	—

Countries

Japan

Contacts

Public ContactHiroyuki Ito

Edogawa Hospital Department of Diabetes, Metabolism and Kidney Disease

ito@edogawa.or.jp03-3673-1221

Outcome results